(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 October 2011 (13.10.2011)

PCT

(10) International Publication Number
WO 2011/123946 A8

(51) International Patent Classification:
C07D 413/14 (2006.01) *A61P 35/00* (2006.01)
A61K 31/5377 (2006.01) *C07D 403/04* (2006.01)

(21) International Application Number:
PCT/CA2011/000386

(22) International Filing Date:
6 April 2011 (06.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/321,329 6 April 2010 (06.04.2010) US
61/321,332 6 April 2010 (06.04.2010) US
PCT/CA2010/000518 6 April 2010 (06.04.2010) CA


(71) Applicant *(for all designated States except US)*: **UNIVERSITY HEALTH NETWORK** [CA/CA]; 190 Elizabeth Street, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SAMPSON, Peter Brent** [CA/CA]; 1320 Ridgebank Drive, Oakville, Ontario L6M 4A5 (CA). **LIU, Yong** [CA/CA]; 65 Forest Manor Road, Apt. 1413, North York, Ontario M2J 1M5 (CA). **LI, Sze-Wan** [CA/CA]; B326 Beverly Street, Toronto, Ontario M5T 3L2 (CA). **FORREST, Bryan T.** [CA/CA]; 9 Fairview Avenue, Toronto, Ontario M6P 3A2 (CA). **PAULS, Heinz W.** [CA/CA]; 460 Fourth Line, Oakville, Ontario L6L 5A4 (CA). **EDWARDS, Louise G.** [CA/CA]; 871 Chippenham Drive, Mississauga, Ontario L5H 3S6 (CA). **FEHER, Miklos** [CA/CA]; 481 Rosewell Avenue, Suite 213, Toronto, Ontario M4R 2J1 (CA). **PATEL, Narendra Kumar B.** [IN/CA]; 1102, 360 Pitfield Road, Scarborough, Ontario M1S 3E6 (CA). **LAUFER, Radoslaw** [CA/CA]; 2145 Meadowglen Drive, Oakville, Ontario L6M 4C8 (CA). **PAN, Guohua** [CA/CA]; 182 Trelawn Avenue, Oakville, Ontario L6J 4R2 (CA).


[Continued on next page]

(54) Title: KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME



(I)

(57) Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: (I). Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.



The Figure Compound example A23 in HUV-EC Cell Tube Formation Assay

WO 2011/123946 A8

(74) **Agents**: **ERRATT, Judy A.** et al.; Gowling Lafleur Henderson LLP, 160 Elgin Street, Suite 2600, Ottawa, Ontario K1P 1C3 (CA).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(48) **Date of publication of this corrected version**:
8 December 2011

(15) **Information about Correction**:
see Notice of 8 December 2011